服用新型口服抗凝药患者缺血性卒中发生率更高
这项回顾性研究比较了服用新型口服抗凝药(NOAC)与华法林患者的卒中相对发生率,数据包括71365例NOAC患者和59546例华法林患者,另有7033例两药均使用的患者作为独立队列。结果显示NOAC组缺血性卒中频率显著更高(OR=1.29,P<0.001),但颅内出血和非创伤性出血发生率更低。
要点
- 服用NOAC患者缺血性卒中频率显著高于华法林患者(OR=1.29,P<0.001)。
- 每种NOAC的缺血性卒中相对频率均高于华法林,其中达比加群和艾沙利酮(阿哌沙班)差异有统计学意义。
- NOAC组颅内出血及非创伤性出血发生率低于华法林组,与已发表文献一致。
核心结论
- NOAC使用与比华法林更高的缺血性卒中风险及更低的出血风险相关,据此可认为服用华法林的患者抗凝更强。
- 观察到的效应可能是剂量控制的次要结果,也可能是不同药物抗凝效应不同的结果。
研究设计与样本
- 回顾性研究,比较服用NOAC与服用华法林两组患者的卒中相对发生率。
- 使用包含71365例NOAC患者和59546例华法林患者的数据集,另将7033例有华法林和NOAC使用记录的患者作为独立队列分析。
- 采用比值比(OR)和Fisher精确检验进行显著性比较。
主要发现
- NOAC组缺血性卒中频率显著高于华法林组(OR=1.29,P<0.001)。
- 每种NOAC的缺血性卒中相对频率均高于华法林,其中达比加群和艾沙利酮(阿哌沙班)差异有统计学意义,依度沙班和利伐沙班未达统计学显著。
- NOAC组颅内出血及非创伤性出血发生率低于华法林组,与已发表文献一致。
- NOAC组与华法林组人口学和临床特征比较未显示NOAC患者基线卒中风险显著更高,实际上NOAC患者总体缺血性卒中基线风险倾向更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The increased use of novel oral anticoagulants (NOACs) to control atrial fibrillation is largely driven by the assumption that they are equally effective as warfarin at preventing ischemic stroke while putting patients at lower risk of hemorrhages. To test this hypothesis, a retrospective study of the relative incidence of strokes among patients taking NOACs versus those taking warfarin is performed. Methods- Relative stroke incidence in the 2 groups of patients was compared using odds ratios and Fisher exact tests for significance using a data set of 71 365 on NOACs and 59 546 patients on warfarin. In addition, the 7033 patients with a record of both warfarin and NOAC use were analyzed as a separate cohort. Results- There is a significantly higher (odds ratio=1.29, <0.001) frequency of ischemic strokes among patients prescribed NOACs compared with those on warfarin. The relative frequency of ischemic strokes was also higher for every individual NOAC compared with warfarin (these higher frequencies are statistically significant for dabigatran and apixaban, though not for edoxaban and rivaroxaban). There is a lower incidence of intracranial hemorrhages and nontraumatic hemorrhages in general among patients taking NOACs, consistent with the published literature. Comparisons of the demographic and clinical profiles of the patients taking NOACs to those on warfarin do not show significantly higher background stroke risk in NOAC patients; in fact, patients on NOACs tend to be at lower background risk overall for ischemic strokes. Conclusions- Because NOAC use is associated with higher ischemic stroke risk together with a lower risk of hemorrhages than warfarin use, it can be concluded that patients on warfarin are more strongly anticoagulated. The observed effect could be a secondary consequence of dosage control or alternatively a result of different anticoagulant effects among the different medications.
引用
- Shpak M, Ramakrishnan A, Nadasdy Z, et al. Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants. Stroke. 2018. PMID: 30571404. doi:10.1161/STROKEAHA.118.022636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。